Urocortin (Human)

Documents

Asp-Asn-Pro-Ser-Leu-Ser-Ile-Asp-Leu-Thr-Phe-His-Leu-Leu-Arg-Thr-Leu-Leu-Glu-Leu-Ala-Arg-Thr-Gln-Ser-Gln-Arg-Glu-Arg-Ala-Glu-Gln-Asn-Arg-Ile-Ile-Phe-Asp-Ser-Val-NH₂
: (M.W. 4696.2) C₂₀₄H₃₃₇N₆₃O₆₄
: Ligand for Type 1/Type 2 CRF Receptors

Package	Price(Yen)	Availability
Vial 0.1 mg	14,000	Ships within 1-3 business days
Bulk Request

Solubility: 0.1% AcOH (0.1 mM)

C.J. Donaldson, S.W. Sutton, M.H. Perrin, A.Z. Corrigan, K.A. Lewis, J.E. Rivier, J.M. Vaughan, and W.W. Vale, Endocrinology, 137, 2167 (1996). (Original; cDNA & Pharmacol.)
D.P. Behan, O. Khongsaly, N. Ling, and E.B. De Souza, Brain Res., 725, 263 (1996). (Biochem.)
Y. Murakami, T. Mori, K. Koshimura, M. Kurosaki, T. Hori, N. Yanaihara, and Y. Kato, Endocr. J., 44, 627 (1997). (Pharmacol.)
K. Takahashi, K. Totsune, M. Sone, O. Murakami, F. Satoh, Z. Arihara, H. Sasano, K. Iino, and T. Mouri, Peptides, 19, 643 (1998). (Immunohistochem.)
C.L. Chang and S.Y.T. Hsu, Peptides, 25, 1681 (2004). (Review)
E.A. Woodcock, Endocrinology, 145, 21 (2004). (Review)
Y. Kuperman and A. Chen, Trends Endocrinol. Metab., 19, 122 (2008). (Review)
W.H. Pan and A.J. Kastin, Prog. Neurobiol., 84, 148 (2008). (Review)
P. Boonprasert, N. Lailerd, and N. Chattipakorn, Int. J. Cardiol., 127, 307 (2008). (Review)

Data Sheet